.png){kind=logo}
Chamberlain University
NR 546 / NR546
Week 3 Antipsychotics Table
Course: Advanced Pharmacology
- / 2
Drug name Indica�on
Target symptoms: state if posi�ve or nega�ve
e�ect Potency (if noted. receptor occupancy if noted ) Neurotransmi�er(s) a�ected Half-life (T1/2), metabolism (CYP 450 enzyme) Notable side e�ects (associate to pathway or NT) Typical an�psycho�cs (conven�onal)
Haloperidol Target Symptoms:
Bipolar Disorder Psycho�c disorders Behavioral disturbances in demen�as Delirium w/ Lorazepam Schizophrenia Tics and vocal u�erances in Toure�es Syndrome Second line treatment of severe behavior in children of comba�ve explosive hyperexcitability
Potency:
High potency �rst-genera�on
Neurotransmi�ers:
Blocks dopamine 2 receptors, reducing posi�ve symptoms of psychosis and possibly comba�ve, explosive, and hyperac�ve behaviors Blocks dopamine 2 receptors in the nigrostriatal pathway, improving �cs and other symptoms in Toure�e’s syndrome.
Half-Life:
Decanoate is approx.
- weeks
Oral: 12-38 hours
Metabolism:
CYP1A2
CYP2D6
CYP3A4
Notable Side E�ects:
Neurolep�c-induced de�cit syndrome Akathisia Drug-induced Parkinsonism Tardive dyskinesia, Tardive dystonia Risk of poten�ally irreversible involuntary dyskine�c movements may increase with cumula�ve dose and treatment dura�on Galactorrhea, Amenorrhea Dizziness Seda�on Dry mouth, cons�pa�on, urinary reten�on, blurred vision Decreased swea�ng Hypotension Tachycardia Hypertension Weight gain
Thioridazine Target Symptoms:
Schizophrenia
Potency:
Low-potency �rst-genera�on
Neurotransmi�ers:
Blocks dopamine 2 receptors, reducing posi�ve symptoms of psychosis
Half-Life:
21-24 Hours
Metabolism:
CYP450 2D6
Notable Side E�ects:
Neurolep�c-induced de�cit syndrome Akathisia Priapism Drug- induced parkinsonism Tardive dyskinesia Risk of poten�ally irreversible involuntary dyskine�c movements may increase with cumula�ve dose Downloaded by Benjamin Luca ([email protected]) lOMoARcPSD 51648332
- / 2
.png)